Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Changes in Stockholders??? Equity (Deficit)

v3.23.1
Consolidated Statements of Changes in Stockholders’ Equity (Deficit) - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2020   56,371      
Beginning balance at Dec. 31, 2020 $ (1,979) $ 6 $ 144,156 $ (145,803) $ (338)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options, net of vesting of restricted shares (in shares)   261      
Exercise of stock options, net of vesting of restricted shares 179   179    
Release of restricted stock (in shares)   2,494      
Issuance of common stock under the 2018 employee stock purchase plan (in shares)   84      
Issuance of common stock under the 2018 employee stock purchase plan 100   100    
Issuance of common stock for payment of board of director fees (in shares)   99      
Issuance of common stock for payment of board of director fees 66   66    
Sale of common stock, net of issuance costs (in shares)   35,383      
Sales of common stock, net of issuance costs 94,737 $ 4 94,733    
Common stock issued pursuant to warrant exercises (in shares)   2,060      
Common stock issued pursuant to warrant exercises 20,782   20,782    
Stock-based compensation expense 4,928   4,928    
Cumulative translation adjustment (14)       (14)
Net loss (53,522)     (53,522)  
Ending balance (in shares) at Dec. 31, 2021   96,752      
Ending balance at Dec. 31, 2021 65,277 $ 10 264,944 (199,325) (352)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options, net of vesting of restricted shares (in shares)   46      
Exercise of stock options, net of vesting of restricted shares 28   28    
Release of restricted stock (in shares)   1,803      
Issuance of common stock under the 2018 employee stock purchase plan (in shares)   205      
Issuance of common stock under the 2018 employee stock purchase plan 214   214    
Issuance of common stock in connection with acquisition of Lyte Technology, Inc. (in shares)   1,724      
Issuance of common stock in connection with acquisition of Lyte Technology, Inc. 3,064   3,064    
Sale of common stock, net of issuance costs (in shares)   2,623      
Sales of common stock, net of issuance costs 4,298   4,298    
Stock-based compensation expense 3,014   3,014    
Cumulative translation adjustment (120)       (120)
Net loss (50,894)     (50,894)  
Ending balance (in shares) at Dec. 31, 2022   103,153      
Ending balance at Dec. 31, 2022 $ 24,881 $ 10 $ 275,562 $ (250,219) $ (472)